EUVIMEDEUVIMED entdecken
Open Access

Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment

Colton Duncan iD, Suraj Sarvode Mothi, Teresa C Santiago, Jordan A Coggins, Dylan E Graetz, Michael W Bishop, Elizabeth A Mullen, Andrew J Murphy, Daniel M Green, Matthew J Krasin, Andrew M Davidoff iD

JNCI: Journal of the National Cancer Institute · 01.08.2024 · 116 (8) · 1230-1237

DOI: 10.1093/jnci/djae072 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, online erschienen am 27.03.2024. Verfasst von Colton Duncan und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Surgery, St Jude Children's Research Hospital, Memphis, TN, USA. Hauptthemen laut MEDLINE: Wilms Tumor, Kidney Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Cancer Center Support, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with bilateral Wilms tumor initially receive neoadjuvant chemotherapy to shrink the tumors and increase the likelihood of successful nephron-sparing surgery. Biopsy of poorly responding tumors is often done to better understand therapy resistance. The purpose of this retrospective, single-institution study was to determine whether initial chemotherapy response is associated with tumor histology, potentially obviating the need for biopsy or change in chemotherapy.

Methods

Patients with synchronous bilateral Wilms tumors who underwent surgery at St Jude Children’s Research Hospital from January 2000 to March 2022 were considered for this study. A mixed-effects logistic regression model was used to evaluate the likelihood of the tumor being stromal predominant, as predicted by tumor response to neoadjuvant chemotherapy.

Results

A total of 68 patients were eligible for this study. Tumors that increased in size had an odds ratio of 19.5 (95% confidence interval [CI] = 2.46 to 155.03) for being stromal predominant vs any other histologic subtype. Age at diagnosis was youngest in patients with stromal-predominant tumors, with a mean age of 18.8 (14.1) months compared with all other histologic subtypes (χ2 = 7.05, P = .07). The predictive value of a tumor growing combined with patient aged younger than 18 months for confirming stromal-predominant histology was 85.7% (95% CI = 57.18% to 93.5%).

Conclusions

Tumors that increased in size during neoadjuvant chemotherapy were most frequently stromal-predominant bilateral Wilms tumor, especially in younger patients. Therefore, nephron-sparing surgery, rather than biopsy, or extension or intensification of neoadjuvant chemotherapy, should be considered for bilateral Wilms tumors that increase in volume during neoadjuvant chemotherapy, particularly in patients aged younger than 18 months.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Wilms TumorKidney NeoplasmsNeoadjuvant TherapyHumansMaleFemaleRetrospective StudiesInfantChild, PreschoolAntineoplastic Combined Chemotherapy ProtocolsNephrectomyTreatment Outcome

Autor:innen und Institutionen

  • Departments of Surgery, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Departments of Biostatistics, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Departments of Pathology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Departments of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Departments of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA.
  • Department of Pediatric Hematology/Oncology, Dana-Farber Cancer Institute, Boston Children's Hospital, Boston, MA, USA.

ORCID-Profile: Colton Duncan, Andrew M Davidoff

Förderung

  • NCI NIH HHS
  • Cancer Center Support
  • National Cancer Institute

Zitieren

APA

Duncan, C., Sarvode Mothi, S., Santiago, T. C., Coggins, J. A., Graetz, D. E., Bishop, M. W., Mullen, E. A., Murphy, A. J., Green, D. M., Krasin, M. J., & Davidoff, A. M. (2024). Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment. JNCI: Journal of the National Cancer Institute, 116(8), 1230-1237. https://doi.org/10.1093/jnci/djae072

Vancouver

Duncan C, Sarvode Mothi S, Santiago TC, Coggins JA, Graetz DE, Bishop MW, et al. Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment. JNCI: Journal of the National Cancer Institute. 2024;116(8):1230-1237. doi:10.1093/jnci/djae072

BibTeX
@article{Duncan2024,
  author = {Duncan, Colton and Sarvode Mothi, Suraj and Santiago, Teresa C and Coggins, Jordan A and Graetz, Dylan E and Bishop, Michael W and Mullen, Elizabeth A and Murphy, Andrew J and Green, Daniel M and Krasin, Matthew J and Davidoff, Andrew M},
  title = {Response of bilateral Wilms tumor to chemotherapy suggests histologic subtype and guides treatment},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  volume = {116},
  number = {8},
  pages = {1230--1237},
  doi = {10.1093/jnci/djae072}
}
Kostenlos starten →